79 related articles for article (PubMed ID: 19135772)
1. Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells.
Hamilton A; Alhashimi F; Myssina S; Jorgensen HG; Holyoake TL
Exp Hematol; 2009 Mar; 37(3):395-401. PubMed ID: 19135772
[TBL] [Abstract][Full Text] [Related]
2. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
3. [Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications].
Zhu HH; Liu YR; Qin YZ; Chang Y; Li JL; Ruan GR; Jiang B; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):441-4. PubMed ID: 17147244
[TBL] [Abstract][Full Text] [Related]
4. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y
Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950
[TBL] [Abstract][Full Text] [Related]
5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
6. Proteasome proteolytic profile is linked to Bcr-Abl expression.
Crawford LJ; Windrum P; Magill L; Melo JV; McCallum L; McMullin MF; Ovaa H; Walker B; Irvine AE
Exp Hematol; 2009 Mar; 37(3):357-66. PubMed ID: 19157685
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
8. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
[TBL] [Abstract][Full Text] [Related]
10. [Effect of G-CSF on the proliferation and differentiation of bcr/abl(+)-CD34+ cells from CML patients].
Li CY; Meng FY; Sun QX; Fu YB; Jiang QL; Yi ZS; Song LL
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):762-5. PubMed ID: 18457269
[TBL] [Abstract][Full Text] [Related]
11. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
13. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
14. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia.
Mancini M; Veljkovic N; Corradi V; Zuffa E; Corrado P; Pagnotta E; Martinelli G; Barbieri E; Santucci MA
Traffic; 2009 Jun; 10(6):637-47. PubMed ID: 19220809
[TBL] [Abstract][Full Text] [Related]
17. [Molecular design and biological activity of BCR-ABL tyrosine kinase inhibitors].
Peng H; Qi J; Huang N; Xie P; Wang JX; Yang CZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):145-9. PubMed ID: 15171550
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
Shi Y; Li LZ; Sun JZ; Zhang T; Peng J; Xu CG
Ann Hematol; 2008 Jan; 87(1):35-41. PubMed ID: 17846772
[TBL] [Abstract][Full Text] [Related]
19. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A
Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
